Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Androgen receptor blocker approved for cancer that progresses despite low testosterone levels.
Patients treated with immunotherapy had a 30 percent reduction in the risk of death.
Erleada delayed cancer progression and death by two years in a Phase III trial.
Xtandi and Erleada both prolonged the time to disease progression or death by about two years.
Immunotherapy combo was more effective and better tolerated for first-time treatment.
Are immunotherapy and targeted therapies ready to replace toxic chemotherapy?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.